

RECEIVED
CENTRAL FAX CENTER

DEC 15 2008

This facsimile message and its contents are legally privileged and confidential information intended solely for the use of the addressee. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, copying or other use of this message and its contents is strictly prohibited. If you have received this telecopy in error, please notify us immediately by telephone and return the original message to us at the address shown below via the Postal Service. Thank You.

ALSTON & BIRD LLP

3201 Beechleaf Court, Suite 600
Raleigh, NC 27604-1062
919-862-2200
Fax: 919-862-2260

URGENT

TELECOPY

PLEASE DELIVER AS SOON AS POSSIBLE

Date:

December 15, 2008

Recipient:

Examiner Anne R. Kubelik

Company:

US Patent & Trademark Office
Art Unit 1638

Fax Number:

571-273-8300

Voice Number:

5761-272-0801

Sender:

Destiny M. Davenport

Message:

Re: Interview with Examiner 12/16/08 for
U.S. Utility Application for *AXMI-007, A Delta-Endotoxin
Gene and Methods for Its Use*
Appl. No. 10/782,570; Filed February 19, 2004
Our File 045600/274144

Number of Pages: (including cover page) 2

IF NOT RECEIVED PROPERLY, PLEASE NOTIFY US IMMEDIATELY AT 919-862-2221.

USER CODE: DAVEN	REQUESTED BY: Nora C. Martinez
CLIENT/MATTER: 045600/274144	OPERATOR:

RECEIVED
CENTRAL FAX CENTER

DEC 15 2008

ALSTON & BIRD LLP

TO: Examiner Anne R. Kubelik (571-272-0801)
Art Unit 1638

FROM: Destiny M. Davenport

DATE: December 15, 2008

RE: U.S. Utility Application for *AXMI-007, A Delta-Endotoxin
Gene and Methods for Its Use*
Appl. No. 10/782,570; Filed February 19, 2004
Our File 045600/274144

This memorandum is sent to set forth the attendees and bullet points for discussion at the personal interview to be held at your office on Tuesday, December 16, 2008 at 2:00 p.m.

Attendees will be:

Destiny M. Davenport, Patent Agent
W. Murray Spruill, Attorney
Nicholas Duck, Inventor
Brian Var de Berg, Inventor

Anne R. Kubelik, Examiner

Points to be discussed:

- Discuss written description and enablement rejections of variant sequences.

DMD:nem

cc: Destiny M. Davenport
W. Murray Spruill

LEGAL02/31057702v1